No Pharma Prognosis In Senate Finance Committee Health Care Priorities
This article was originally published in The Tan Sheet
While Senate Finance Chairman Hatch wants to tackle health care topics including chipping away at the Affordable Care Act and reforming the Medicare sustainable growth rate for physician pay, pharma- and supplement-related topics are not on his priority list. Patrick Toomey chairs the Health Subcommittee.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.